Evidence map›Paper›PMID 40753362›Full record

ArticleEJNMMI research2025

Blood-based transcriptomic biomarkers for response to [

Hyunpil Sung, Sungwoo Bae, Minseok Suh, Hongyoon Choi, Hyung-Jun Im, Gi Jeong Cheon, Keon Wook Kang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Combination therapy strategies in engineeredCell communication and signaling : CCS · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hyunpil Sung *Department of Nuclear Medicine, Seoul National University Hospital, 03080, Seoul, Republic of Korea.
Sungwoo Bae *Radiation Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Minseok SuhDepartment of Nuclear Medicine, Seoul National University Hospital, 03080, Seoul, Republic of Korea.
Hongyoon ChoiDepartment of Nuclear Medicine, Seoul National University Hospital, 03080, Seoul, Republic of Korea. chy1000@snu.ac.kr.ORCID http://orcid.org/0000-0002-8895-2449
Hyung-Jun ImDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea. iiihjjj@snu.ac.kr.
Gi Jeong CheonDepartment of Nuclear Medicine, Seoul National University Hospital, 03080, Seoul, Republic of Korea.
Keon Wook KangDepartment of Nuclear Medicine, Seoul National University Hospital, 03080, Seoul, Republic of Korea.

Funding

Korea Evaluation Institute of Industrial Technology 20018522Korea Health Industry Development Institute RS-2024-00439394National Research Foundation of Korea NRF-2022M3A9D3016848National Research Foundation of Korea NRF- 2023R1A2C2006636National Research Foundation of Korea RS-2025-00564094
6 · The paper itself

Abstract

background[

resultsTwenty-six patients were prospectively enrolled in this study. Responders were defined as patients who showed partial response or stable disease and non-responders were defined as patients who showed progressive disease according to RECIST1.1 criteria. Of the 26 patients, responders (n = 20) exhibited distinct gene expression profiles compared to non-responders (n = 6). Among the 21 differentially expressed genes identified between the groups, 13 genes were upregulated in non-responders and were associated with the innate immune system. Weighted Gene Co-expression Network Analysis identified a significant gene module linked to treatment response, with eEF1A1 emerging as a key hub gene correlated with favorable outcomes. Baseline clinical and laboratory parameters did not differ significantly according to treatment response.

conclusionsThis study identifies specific blood transcriptomic profiles associated with the innate immune response and a key hub gene linked to treatment outcomes, suggesting an immune-related component in response to [

Indexed as

[177Lu]Lu-DOTA-TATEBlood biomarkerNeuroendocrine tumorRNA sequencing

Identifiers

PMID40753362
PMCPMC12317932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.